Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Resverlogix amended the trial design long ago to allow patients to be dosed beyond 104 weeks. They previously communicated that patients will continue dosing until end of study. In both the January and February presentations this year they used the language of dosing up to 3 years. This was not new to yesterday's presentation.
